25mg Eluxadoline + 100mg Eluxadoline
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Irritable Bowel Syndrome
Conditions
Irritable Bowel Syndrome
Trial Timeline
Aug 13, 2021 → Dec 1, 2032
NCT ID
NCT04880876About 25mg Eluxadoline + 100mg Eluxadoline
25mg Eluxadoline + 100mg Eluxadoline is a phase 3 stage product being developed by AbbVie for Irritable Bowel Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04880876. Target conditions include Irritable Bowel Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04880876 | Phase 3 | Recruiting |
Competing Products
20 competing products in Irritable Bowel Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| linaclotide + placebo | Astellas Pharma | Phase 2 | 52 |
| YM060 + Placebo | Astellas Pharma | Phase 3 | 77 |
| Ramosetron + Placebo | Astellas Pharma | Approved | 85 |
| Ramosetron + Placebo | Astellas Pharma | Approved | 85 |
| YM060 | Astellas Pharma | Phase 3 | 77 |
| YM060 + placebo | Astellas Pharma | Phase 2 | 52 |
| YM060 | Astellas Pharma | Phase 3 | 77 |
| linaclotide + Placebo | Astellas Pharma | Phase 3 | 77 |
| Ramosetron | Astellas Pharma | Pre-clinical | 23 |
| YM060 | Astellas Pharma | Phase 2 | 52 |
| ONO-2952 + Placebo comparator | Ono Pharmaceutical | Phase 2 | 52 |
| ONO-2952 + ONO-2952 Matching Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| duloxetine | Eli Lilly | Approved | 85 |
| Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers) | AbbVie | Phase 3 | 77 |
| Eluxadoline + Placebo | AbbVie | Phase 2 | 52 |
| Placebo + Linaclotide | AstraZeneca | Phase 3 | 77 |
| Tegaserod | Novartis | Pre-clinical | 23 |
| DNK333 | Novartis | Phase 2 | 52 |
| SMS995 + Placebo | Novartis | Phase 1 | 33 |
| DNK333 + Placebo | Novartis | Phase 2 | 52 |